Rockwell Medical Extends Product Purchase Agreement with aQua Dialysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Rockwell Medical announced that the Company has renewed and extended its product purchase agreement with aQua Dialysis a leading independent provider of in-center hemodialysis and home dialysis services in Texas. The Agreement, which includes supply and purchasing commitments, will be in effect for two years with options to renew for two additional one-year periods. Under the Agreement, Rockwell Medical will continue to supply aQua Dialysis with the Company's liquid and dry, acid and bicarbonate hemodialysis concentrates and other essential dialysis related products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RMTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RMTI
Wall Street analysts forecast RMTI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.697
Low
2.50
Averages
3.75
High
5.00
Current: 0.697
Low
2.50
Averages
3.75
High
5.00
About RMTI
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rockwell Medical Renews Agreement with aQua Dialysis
- Agreement Renewal: Rockwell Medical has renewed its two-year product purchase agreement with aQua Dialysis in Texas, with options for two additional one-year extensions, ensuring stable product supply and enhancing the company's competitive position in the market.
- Supply Commitment: Under the agreement, Rockwell Medical will continue to supply aQua Dialysis with liquid and dry acid and bicarbonate hemodialysis concentrates and other essential dialysis-related products, which not only solidifies their long-term partnership but also boosts customer trust in product quality.
- Strengthened Customer Relations: Tim Chole, Chief Commercial Officer of Rockwell Medical, stated that the renewal reflects the strong relationship with aQua Dialysis, indicating high customer recognition of the company's product quality and service, further enhancing brand value.
- Industry Impact: Rockwell Medical is committed to providing high-quality products and services for dialysis patients, and with its strong reputation and reliability in the industry, it is expected to attract more customers and partners, driving long-term growth for the company.
See More
Rockwell Medical Enters Three-Year Purchase Agreement with Heritage Dialysis
- Strategic Partnership: Rockwell Medical has signed a three-year product purchase agreement with Michigan-based Heritage Dialysis, covering a range of hemodialysis products including the 720g bicarbonate cartridge PureCart, aimed at meeting Heritage Dialysis's flexible needs across various environments, thereby enhancing competitive positioning for both parties.
- Product Portfolio Advantage: Under the agreement, Rockwell Medical will supply Heritage Dialysis with products such as liquid acetic acid-based RenalPure® and liquid bicarbonate SteriLyte®, which will support Heritage Dialysis's operations in home dialysis and skilled nursing facilities, improving patient treatment experiences.
- Long-Term Growth Potential: Ryan Height, Founder and CEO of Heritage Dialysis, stated that the collaboration will transform renal care by combining state-of-the-art technology with optimal treatment plans, which is expected to provide better health and wellness for patients, further solidifying Rockwell Medical's position in the industry.
- Industry Recognition: Rockwell Medical has been certified as a Great Place to Work® for four consecutive years and named Fortune's Best Workplaces in Manufacturing & Production™ for 2024 and 2025, demonstrating its commitment to delivering high-quality dialysis solutions and customer service, which enhances its market appeal.
See More
Rockwell Medical Q1 2026 Earnings Call Insights
- Profitability Outlook: CEO Mark Strobeck indicated that Rockwell Medical aims for positive net income in the second half of 2026, despite customary risks and uncertainties, marking a significant step towards sustainable profitability.
- Sales Performance Review: The first quarter net sales reached $17.3 million, exceeding expectations but declining year-over-year due to reduced volumes from the largest customers, highlighting the risk of customer concentration.
- Automation Investment: The company plans to activate two new automated liquid production lines this quarter, which are expected to increase output by approximately 50% and significantly reduce manufacturing costs per bottle, potentially generating an additional $3 million in gross profit in 2026.
- Annual Guidance Update: Management provided guidance for 2026, projecting net sales between $70 million and $75 million, gross margins of 18% to 22%, and adjusted EBITDA of $1 million to $2 million, indicating a path towards positive cash flow and profitability in the future.
See More
Rockwell Medical Reports Q1 Earnings Miss with Updated 2026 Guidance
- Earnings Report Miss: Rockwell Medical's Q1 non-GAAP EPS stands at -$0.01 with revenue of $17.34 million, reflecting an 8.3% year-over-year decline and missing expectations by $0.61 million, indicating adverse effects from reduced purchase volumes by a key customer.
- Customer Purchase Decline: The decrease in net sales is primarily attributed to a reduction in purchase volume from one of the company's customers, which may impact future revenue stability and market share.
- 2026 Guidance Update: The company has updated its 2026 annual guidance, projecting net sales between $70 million and $75 million, with a gross margin target of 18% to 22%, reflecting a cautiously optimistic outlook for future growth.
- Cash Flow and EBITDA Expectations: Rockwell Medical anticipates adjusted EBITDA of $1 million to $2 million in 2026 and aims for positive operating cash flow, indicating that efforts to diversify its product mix may gradually yield results.
See More
Rockwell Medical to Announce Q1 Earnings on May 7
- Earnings Announcement: Rockwell Medical (RMTI) is set to announce its Q1 2023 earnings on May 7 before market open, with a consensus EPS estimate of -$0.03, reflecting a significant 200% year-over-year decline.
- Revenue Decline: The company anticipates Q1 revenue of $17.95 million, representing a 5.1% year-over-year decrease, indicating challenges in the competitive healthcare market.
- Historical Performance: Over the past two years, RMTI has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, suggesting some capacity for exceeding expectations, though improvement is needed.
- Future Outlook: Rockwell Medical aims for an adjusted EBITDA of $1 million to $2 million and positive cash flow in 2026, indicating a strategic focus on diversifying its product mix to drive future growth.
See More
Rockwell Medical Announces Q1 2026 Financial Results Release Schedule
- Results Release Schedule: Rockwell Medical will release its financial and operational results for Q1 2026 on May 7, 2026, with a press release at 6:00 AM ET followed by a live webcast at 8:00 AM ET, ensuring timely access to critical information for investors.
- Webcast Details: The webcast will be hosted by President and CEO Mark Strobeck, Ph.D., and CFO Jesse Neri, featuring a discussion of the Q1 results followed by a Q&A session, aimed at enhancing investor engagement and transparency.
- Company Overview: Rockwell Medical focuses on developing, manufacturing, and commercializing hemodialysis products, committed to providing high-quality products and exceptional customer service to dialysis providers worldwide, highlighting its significance in the healthcare sector.
- Industry Recognition: Rockwell Medical has been certified as a Great Place to Work® for four consecutive years and named one of Fortune's Best Workplaces in Manufacturing & Production™ in 2024 and 2025, reflecting the company's ongoing commitment to employee satisfaction and industry reputation.
See More
Rockwell Medical Renews Agreement with aQua Dialysis
- Agreement Renewal: Rockwell Medical has renewed its two-year product purchase agreement with aQua Dialysis in Texas, with options for two additional one-year extensions, ensuring stable product supply and enhancing the company's competitive position in the market.
- Supply Commitment: Under the agreement, Rockwell Medical will continue to supply aQua Dialysis with liquid and dry acid and bicarbonate hemodialysis concentrates and other essential dialysis-related products, which not only solidifies their long-term partnership but also boosts customer trust in product quality.
- Strengthened Customer Relations: Tim Chole, Chief Commercial Officer of Rockwell Medical, stated that the renewal reflects the strong relationship with aQua Dialysis, indicating high customer recognition of the company's product quality and service, further enhancing brand value.
- Industry Impact: Rockwell Medical is committed to providing high-quality products and services for dialysis patients, and with its strong reputation and reliability in the industry, it is expected to attract more customers and partners, driving long-term growth for the company.
See More
Rockwell Medical Enters Three-Year Purchase Agreement with Heritage Dialysis
- Strategic Partnership: Rockwell Medical has signed a three-year product purchase agreement with Michigan-based Heritage Dialysis, covering a range of hemodialysis products including the 720g bicarbonate cartridge PureCart, aimed at meeting Heritage Dialysis's flexible needs across various environments, thereby enhancing competitive positioning for both parties.
- Product Portfolio Advantage: Under the agreement, Rockwell Medical will supply Heritage Dialysis with products such as liquid acetic acid-based RenalPure® and liquid bicarbonate SteriLyte®, which will support Heritage Dialysis's operations in home dialysis and skilled nursing facilities, improving patient treatment experiences.
- Long-Term Growth Potential: Ryan Height, Founder and CEO of Heritage Dialysis, stated that the collaboration will transform renal care by combining state-of-the-art technology with optimal treatment plans, which is expected to provide better health and wellness for patients, further solidifying Rockwell Medical's position in the industry.
- Industry Recognition: Rockwell Medical has been certified as a Great Place to Work® for four consecutive years and named Fortune's Best Workplaces in Manufacturing & Production™ for 2024 and 2025, demonstrating its commitment to delivering high-quality dialysis solutions and customer service, which enhances its market appeal.
See More
Rockwell Medical Q1 2026 Earnings Call Insights
- Profitability Outlook: CEO Mark Strobeck indicated that Rockwell Medical aims for positive net income in the second half of 2026, despite customary risks and uncertainties, marking a significant step towards sustainable profitability.
- Sales Performance Review: The first quarter net sales reached $17.3 million, exceeding expectations but declining year-over-year due to reduced volumes from the largest customers, highlighting the risk of customer concentration.
- Automation Investment: The company plans to activate two new automated liquid production lines this quarter, which are expected to increase output by approximately 50% and significantly reduce manufacturing costs per bottle, potentially generating an additional $3 million in gross profit in 2026.
- Annual Guidance Update: Management provided guidance for 2026, projecting net sales between $70 million and $75 million, gross margins of 18% to 22%, and adjusted EBITDA of $1 million to $2 million, indicating a path towards positive cash flow and profitability in the future.
See More
Rockwell Medical Reports Q1 Earnings Miss with Updated 2026 Guidance
- Earnings Report Miss: Rockwell Medical's Q1 non-GAAP EPS stands at -$0.01 with revenue of $17.34 million, reflecting an 8.3% year-over-year decline and missing expectations by $0.61 million, indicating adverse effects from reduced purchase volumes by a key customer.
- Customer Purchase Decline: The decrease in net sales is primarily attributed to a reduction in purchase volume from one of the company's customers, which may impact future revenue stability and market share.
- 2026 Guidance Update: The company has updated its 2026 annual guidance, projecting net sales between $70 million and $75 million, with a gross margin target of 18% to 22%, reflecting a cautiously optimistic outlook for future growth.
- Cash Flow and EBITDA Expectations: Rockwell Medical anticipates adjusted EBITDA of $1 million to $2 million in 2026 and aims for positive operating cash flow, indicating that efforts to diversify its product mix may gradually yield results.
See More
Rockwell Medical to Announce Q1 Earnings on May 7
- Earnings Announcement: Rockwell Medical (RMTI) is set to announce its Q1 2023 earnings on May 7 before market open, with a consensus EPS estimate of -$0.03, reflecting a significant 200% year-over-year decline.
- Revenue Decline: The company anticipates Q1 revenue of $17.95 million, representing a 5.1% year-over-year decrease, indicating challenges in the competitive healthcare market.
- Historical Performance: Over the past two years, RMTI has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, suggesting some capacity for exceeding expectations, though improvement is needed.
- Future Outlook: Rockwell Medical aims for an adjusted EBITDA of $1 million to $2 million and positive cash flow in 2026, indicating a strategic focus on diversifying its product mix to drive future growth.
See More
Rockwell Medical Announces Q1 2026 Financial Results Release Schedule
- Results Release Schedule: Rockwell Medical will release its financial and operational results for Q1 2026 on May 7, 2026, with a press release at 6:00 AM ET followed by a live webcast at 8:00 AM ET, ensuring timely access to critical information for investors.
- Webcast Details: The webcast will be hosted by President and CEO Mark Strobeck, Ph.D., and CFO Jesse Neri, featuring a discussion of the Q1 results followed by a Q&A session, aimed at enhancing investor engagement and transparency.
- Company Overview: Rockwell Medical focuses on developing, manufacturing, and commercializing hemodialysis products, committed to providing high-quality products and exceptional customer service to dialysis providers worldwide, highlighting its significance in the healthcare sector.
- Industry Recognition: Rockwell Medical has been certified as a Great Place to Work® for four consecutive years and named one of Fortune's Best Workplaces in Manufacturing & Production™ in 2024 and 2025, reflecting the company's ongoing commitment to employee satisfaction and industry reputation.
See More
